Growth Fund Sells $20 Million in Novanta Stock as Headwinds Weigh on Returns

Conestoga Capital Advisors divested 168,907 shares of Novanta (NOVT) for an estimated $20.1 million in Q3, reducing its holding to 2.3% of its U.S. equity AUM. This sale follows Novanta's significant stock underperformance, down 26% over the past year, and Q2 results showing flat organic growth and a GAAP profit decline. The move is interpreted as Conestoga's frustration with the stock's weak relative performance amid market trends, rather than a loss of conviction in fundamentals, suggesting a short-term rotation, with future institutional interest contingent on Novanta's ability to reignite organic growth.

Analysis

Conestoga Capital Advisors divested 168,907 shares of Novanta (NOVT) in Q3, totaling an estimated $20.1 million, reducing its stake to 2.3% of its U.S. equity AUM. This transaction follows Novanta's significant underperformance, with its stock down 26% over the past year compared to the S&P 500's 17% gain. The sale, while substantial, leaves Conestoga holding over 1.4 million NOVT shares, indicating a partial rather than full exit.

Conestoga attributes the sale to "frustration with the stock’s weak relative performance and sector headwinds," explicitly stating it is not a loss of conviction in Novanta's fundamentals. The firm noted that precision technology companies like Novanta lagged during a quarter dominated by "low-quality" and "high-beta" stocks, suggesting a broader market rotation away from certain tech segments. This implies the sale is more a tactical adjustment to market dynamics than a fundamental reassessment of Novanta's long-term value.

Operationally, Novanta reported flat organic growth in Q2 and a sharp GAAP profit decline to $4.5 million from $13.8 million year-over-year, though adjusted earnings remained steady at $0.76 per share. Despite these short-term challenges, Novanta's core business in photonics, vision, and precision motion for medical and industrial OEMs aligns with secular growth themes. Future institutional investor interest is explicitly tied to the company's ability to reignite organic growth.

Key Decisions for Investors

• Investors should closely monitor Novanta's (NOVT) ability to reignite organic growth, as this is identified as a key determinant for future institutional interest and a potential catalyst for stock performance.
• Consider the broader market context of tactical rotations, as Conestoga's partial divestment was driven by sector headwinds and relative underperformance in a market favoring "low-quality" and "high-beta" stocks, rather than a fundamental conviction change.
• Evaluate Novanta's long-term secular growth alignment in medical and industrial markets against its recent operational challenges, assessing whether current valuations adequately reflect potential for recovery and sustained growth.